News|Videos|November 19, 2026

Executive Conversations: How Should Manufacturers Reevaluate Their Channel Strategy?

In Episode 2, Part 3, Cheryl Allen, Nick Calla and Rena Goins discuss where manufacturers should start when evaluating the channel.

The second episode of Executive Conversations: The Future of Pharmaceutical Commercialization turns to where manufacturers should start when evaluating their channel strategy. Curatio Advisors partner Cheryl Allen poses the question to Nick Calla, senior vice president of industry relations at Orsini Specialty Pharmacy, and Rena Goins, executive director of commercial trade and distribution at Regeneron Pharmaceuticals.

Goins says the starting point is the patient. Manufacturers should look at their clinical trial work to understand how they identified patients and the best opportunity to get them a trial of the medication. That principle applies to pharmacies as well as manufacturers, she says.

Next, manufacturers need to understand what differentiation their medication will provide to improve the patient's life. Brand and marketing teams then shape the messaging so providers, pharmacies and wholesale and distribution partners understand it. Goins says she has been impressed by how the wholesale distribution community has evolved to want a seat at the table early in conversations about the right model.

Calla builds on Goins' earlier point about core competencies. From his perspective as a provider, manufacturers designing channel partners should focus on what each is truly good at, whether it's a pharmacy, a clinical research organization or a patient services hub, and build the strategy from there.

Catch every episode of Executive Conversations: The Future of Pharmaceutical Commercialization.

The views expressed by the participants are their own and do not necessarily reflect those of the organizations they work for.


Related to this article